Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy

Abstract

Zygomycosis is increasingly reported as a cause of life-threatening fungal infections. A higher proportion of cases reported over the last decades have been in cancer patients, with or without hematopoietic stem cell transplantation (HSCT). The new anti-fungal agent voriconazole is a recently identified risk factor for developing zygomycosis. We reviewed the clinical characteristics and outcomes of a large cohort of cancer patients who developed zygomycosis after exposure to voriconazole. Health care professionals at 13 large cancer centers provided clinical information on cancer patients with zygomycosis and prior exposure to voriconazole. Criteria for inclusion were 5 days or more of voriconazole use and diagnostic confirmation with tissue or histology. Fifty-eight cases were identified among patients with hematologic malignancies, 62% including patients who underwent a HSCT procedure. Fifty-six patients received voriconazole for primary or secondary prophylaxis against fungal infection. In addition to prior exposure to voriconazole, patients also had several of the previously established risk factors for zygomycosis. Amphotericin B was the most commonly prescribed anti-fungal therapy. Overall mortality was 73%. We conclude that zygomycosis after exposure to voriconazole is a recently described entity that is frequently fatal, despite treatment with currently available anti-fungal agents and surgery.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653.

    Article  Google Scholar 

  2. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP . Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60–66.

    Article  Google Scholar 

  3. Marty FM, Cosimi LA, Baden LR . Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952.

    Article  CAS  Google Scholar 

  4. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA . Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743–746.

    Article  Google Scholar 

  5. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584–587.

    Article  Google Scholar 

  6. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: a case control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360.

    Article  Google Scholar 

  7. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR . In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581–1582.

    Article  CAS  Google Scholar 

  8. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM et al. The Research on Adverse Drug Events and Report (RADAR) project. JAMA 2005; 293: 2131–2140.

    Article  CAS  Google Scholar 

  9. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.

    Article  CAS  Google Scholar 

  10. Yarnold PR, Soltysik RC . Optimal Data Analysis: Guidebook with Software for Windows. APA Books: Washington, DC, 2005.

    Google Scholar 

  11. Spellberg B, Edwards Jr J, Ibrahim A . Novel perspectives on Mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev 2005; 18: 556–569.

    Article  CAS  Google Scholar 

  12. Spellberg B, Fu Y, Edwards Jr JE, Ibrahim AS . Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830–832.

    Article  CAS  Google Scholar 

  13. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126–133.

    Article  CAS  Google Scholar 

  14. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP . Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61–e65 (E-pub 2006 Feb 21; erratum in Clin infect Dis 2006; 43: 1376).

    Article  CAS  Google Scholar 

  15. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009–2015.

    Article  CAS  Google Scholar 

  16. Rickerts V, Bohme A, Just-Nubling G . Risk factor for invasive zygomycosis in patients with hematologic malignancies. Mycoses 2002; 45 (Suppl 1): 27–30.

    Article  Google Scholar 

  17. Marr KA, Seidel K, White TC, Bowden RA . Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316.

    Article  CAS  Google Scholar 

  18. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509–513.

    Article  CAS  Google Scholar 

  19. Trifilio S, Singhal S, Williams S, Winter J, Tallman M, Gordon L et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Blood (ASH Annual Meeting Abstracts) 2006, Abstract number 2849.

  20. Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209–212.

    Article  CAS  Google Scholar 

  21. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C L Bennett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trifilio, S., Bennett, C., Yarnold, P. et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39, 425–429 (2007). https://doi.org/10.1038/sj.bmt.1705614

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705614

Keywords

This article is cited by

Search

Quick links